TABLE 1.

Effects of mSpry4 Expression on Islet Development

Age
E19.5
2 wk
4 wk
Dox treatmentE0-E19.5
E0-PN14
E0-PN28
Control*mSpry4Control*mSpry4Control*mSpry4
Islet area (μm2)3,924 ± 3162,930 ± 2676,636 ± 5034,731 ± 4129,766 ± 1,0427,617 ± 718
P0.00040.01850.0788
α Cells/area (per 1,000 μm2)3.91 ± 0.195.1 ± 0.315.48 ± 0.266.97 ± 0.392.76 ± 0.254.22 ± 0.57
P0.00530.00370.0151
Insulin-positive area/total islet area (%)57 ± 236 ± 356 ± 228 ± 268 ± 357 ± 2
P0.00010.00010.0056
Missorted α cells/islet area (per 1,000 μm2)NA1.5 ± 0.132.94 ± 0.260.86 ± 0.121.92 ± 0.3
P0.00010.0003
n = 121n = 132n = 117n = 64n = 54n = 64
N = 9N = 13N = 6N = 7N = 6N = 12
  • NOTE: Values represent mean ± SD. P value of mSpry4 vs control (two-tailed Mann Whitney test). n, number of islets; N, number of mice.

  • Abbreviations: Dox, doxycycline; NA, not applicable.

  • * Rip1rtTA or (tetO)7mSpry4.

  • Rip1rtTA;(tetO)7mSpry4.